36173-52-1

Upstream product

• 91600-19-0 (rac)-1-Benzyl-3-methyl-piperidin-4-ol 
• 1159982-52-1 C₁₄H₂₃NO₅ 
• 181269-69-2 tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate 
• 181269-70-5 trans-tert-butyl-4-hydroxy-3-methylpiperidine-1-carboxylate 
• 790667-50-4 (3,4-trans)-1-benzyl-3-methylpiperidin-4-ol 
• 34737-89-8 1-Benzyl-3-methyl-4-piperidon 
• 790667-50-4 (3R,4R)-1-benzyl-3-methylpiperidin-4-ol 
• 790667-50-4 (+/-)-trans-1-benzyl-3-methylpiperidin-4-ol 
• 17038-84-5 ethyl 1-benzoyl-3-methyl-4-oxo-3-piperidinecarboxylate 
• 4451-86-9 ethyl 1-benzoyl-4-oxopiperidine-3-carboxylate 
• 4629-78-1 3-methylpiperidine-4-one hydrochloride 

Downstream Products

• 955028-90-7 (+/-) tert-butyl trans-4-hydroxy-3-methylpiperidine-1-carboxylate 
• 955028-90-7 rac-(cis)-tert-butyl 4-hydroxy-3-methylpiperidine-1-carboxylate 
• 955028-90-7 (3,4-trans)-tert-butyl 4-hydroxy-3-methylpiperidine-1-carboxylate 
• 1610033-60-7 2-((2S,4R)-1-(4-(((3,4-trans)-1-(2-fluoro-5-methoxyphenyl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methoxypyrrolidin-2-yl)acetonitrile 
• 1610033-59-4 ((2R,4R)-1-(4-(((3,4-trans)-1-(2-fluoro-5-methoxyphenyl)-3-methylpiperidin-4-yl)oxy)phenyl)-4-methoxypyrrolidin-2-yl)methanol 
• 181269-70-5 trans-tert-butyl-4-hydroxy-3-methylpiperidine-1-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTED BENZOXAZOLES

The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.

SUBSTITUTED BENZOXAZOLES

The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.

PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES

The present invention provides compounds of Formula (I) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

PYRROLIDINE GPR40 MODULATORS

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT

A chemical compound represented by the formula [I]: (wherein R 1 represents a hydroxyl group or the like, m represents 0 or an integer of 1 to 5, R 2 represents a halogen atom or the like, k represents 0 or an integer of 1 to 4, R 3 , R 31 , R 4 , R 41 ,

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.

Phencyclidine derivatives, preparation method and pharmaceutical compositions containing same

The invention concerns novel phenylcyclidine derivatives with selective affinity for low affinity receptors, methods for preparing them, pharmaceutical compositions containing them and their use as protective agents for central or peripheral nervous system cells against acute or chronic degeneration, or as an anticonvulsant.

The search for TCP analogues binding to the low affinity PCP receptor sites in the rat cerebellum

With the aim of obtaining selective ligands of the low affinity binding sites of [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine ([3H]TCP) in the rat cerebellum, oxygen and sulfur atoms were introduced in the TCP structure and derivatives to obtain analogues with a lowered lipophilicity. These compounds, and others already obtained, were assayed comparatively to determine their affinities for three sites labeled with [3H]TCP: one in the forebrain, the originally described PCP receptor, and two in the rat cerebellum. Lowering the lipophilicity and modifying the hetero-aromatic moiety yielded some ligands with increased affinity for the low affinity sites in the rat cerebellum and decreased affinity for the high affinity sites in the forebrain. Particularly, two compounds displaying both a high affinity and a good selectivity might be valuable tools to elucidate the pharmacology of the low affinity PCP sites labeled with [3H]TCP in the rat cerebellum.